Bob Bradway with the leadership team of Amgen deCODE genetics.
Bob Bradway, CEO of Amgen, visited the facilities of Amgen deCODE genetics (ADG) on Wednesday, March 11. During the visit he learned about the company’s operations, met with executives and scientists, and addressed all employees in the auditorium together with Dr. Howard Chang, Chief Scientific Officer and SVP Global Research at Amgen.
Bob thanked the staff of Amgen deCODE genetics for the warm welcome and engaging discussions. He said that the research conducted at ADG will continue to enable Amgen to develop medicines and carry out drug research aimed at tackling serious diseases and serving the patients.
He said that drug research and development are undergoing major changes with the emergence and rapid advancement of AI. Amgen intends to remain at the forefront in this field and to further increase its investment in innovation and research.
Bob said he has high expectations for continued collaboration between scientists at ADG and rest of Amgen. Such collaboration is extremely important and a key source of innovation and scientific discovery.
He added that ADG will continue to play a key role in Amgen’s global research efforts.
At the meeting, two scientists from ADG, Guðmundur Logi Nordahl and Doruk Beyter, presented research findings from projects carried out through broad collaboration between scientists at ADG and other Amgensites.
The meeting concluded with Bob and Howard taking questions from employees, followed by a lively discussion.